http://orcid.org/0000-0001-5300-4185
References
- Donnez J, Dolmans M. Uterine fibroid management: from the present to the future. Hum Reprod Update 2016;22:665–86.
- Fuldeore MJ, Soliman AM. Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis. Int J Womens Heal 2017;9:403–11.
- Van De Bosch T, Dueholm M, Leone FPG, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol 2015;46:284–98.
- European Medicines Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002041/human_med_001542.jsp&mid=WC0b01ac058001d124 [last accessed 14 Sep 2017].
- Donnez J, Vázquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014;101:1565–73.e1–18.
- Luyckx M, Squifflet J-L, Jadoul P, et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014;102:1404–9.
- Murad K. Spontaneous pregnancy following ulipristal acetate treatment in a woman with a symptomatic uterine fibroid. J Obstet Gynaecol Canada 2016;38:75–9.
- Ricci S, Stone RL, Fader AN. Gynecologic oncology uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecol Oncol 2017;145:208–16.
- Seagle BL, Sobecki-rausch J, Strohl AE, et al. Gynecologic oncology prognosis and treatment of uterine leiomyosarcoma: a national cancer database study. Gynecol Oncol 2017;145:61–70.
- Mahnert N, Morgan D, Campbell D, et al. Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications. Obstet Gynecol 2015;125:397–405.
- Brohl AS, Li L, Andikyan V, et al. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist 2015;20:433–9.
- Oduyebo T, Hinchcliff E, Meserve EE, et al. Risk factors for occult uterine sarcoma among women undergoing minimally invasive gynecologic surgery. J Minim Invasive Gynecol 2016;23:34–9.
- Cho HY, Kim K, Kim YB, et al. Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics. J Obstet Gynaecol Res 2016;42:313–18.
- Exacoustos C, Romanini ME, Amadio A, et al. Can gray-scale and color Doppler sonography differentiate between uterine. J Clin Ultrasound 2007;35:449–57.
- Bonneau C, Thomassin-naggara I, Dechoux S, et al. Value of ultrasonography and magnetic resonance imaging for the characterization of uterine mesenchymal tumors. Acta Obstet Gynecol Scand 2014;93:261–8.
- Aviram R, Ochshorn Y, Markovitch O, et al. Uterine sarcomas versus leiomyomas: gray-scale and Doppler sonographic findings. J Clin Ultrasound 2004;33:10–13.
- Tasaki A, Asatani MO, Umezu H, et al. Differential diagnosis of uterine smooth muscle tumors using diffusion-weighted imaging: correlations with the apparent diffusion coefficient and cell density. Abdom Imaging 2015;40:1742–52.
- Sato K, Yuasa N, Fujita M, Fukushima Y. Clinical application of diffusion-weighted imaging for preoperative differentiation between uterine leiomyoma and leiomyosarcoma. Am J Obstet Gynecol 2014;210:368.e1–e8.
- Donnez J, Tomaszewski J, Vàsquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421–32.
- Istre O. Unexpected uterine leiomyosarcoma during laparoscopic hysterectomy treated 6 months with ulipristal acetate and contained power morcellation. J Minim Invasive Gynecol 2017;24:198. doi:10.1016/j.jmig.2016.08.004.
- Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016;105:165–73.e4.
- Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015;103:519–27.e3.